The search for new triazole antifungal agents

Current Opinion in Chemical Biology

Volumn 1, Issue 2, 1997, Pages 176-182

  Koltin, Yigal ^a   Hitchcock, Christopher A ^b  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DIFLUOROPHENYL) 1 [3 [2 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL]VINYL] 1,2,4 TRIAZOL 1 YL] 3 (1,2,4 TRIAZOL 1 YL) 2 PROPANOL; ANTIFUNGAL AGENT; NEW DRUG; POSACONAZOLE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

CHEMISTRY; HUMAN; REVIEW;

ANTIFUNGAL AGENTS; DRUGS, INVESTIGATIONAL; HUMANS; PYRIMIDINES; TRIAZOLES;

EID: 0031197111     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(97)80007-5     Document Type: Article

References (52)

1. Bennett JE: Antimicrobial agents: antifungal agents. In Goodman and Gilman's, The Pharmacological Basis of Therapeutics, edn 9. Edited by Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG. New York: McGraw-Hill Inc; 1995:1175-1190.
2. Banerjee SN, Emori G, Culver DH, Gaynes RP, Jarvis WR, Horan T, Edwards JR, Tolson J, Henderson T, Martone WJ and The National Nosocomial Infections Surveillance System: National nosocomial infections surveillance: secular trends in nosocomial primary blood stream infections in the United States, 1980-1989. Am J Med 1991, 91(suppl 36):86-89.
3. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC: Candidemia in a tertiary care hospital: epidemiology, risk factors and predictors of mortality. Clin Infect Dis 1992, 14:414-421.
4. Denning DW, Stevens DA: Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990, 12:1147-1201.
5. Hiemenz JW, Walsh TJ: Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996, 22(suppl 2):133-144. A useful vignette of current and emerging liposomal formulations of amphotericin B and the development issues that require to be addressed before they can replace raw amphotericin B as first line therapy.
6. Hartsel S, Bolard J: Amphotericin B: new life for an old drug. Trends Pharmacol Sci 1996, 17:445-449.
7. Goa KL, Barradell LB: Fluconazole: an update on its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1996, 50:658-690. A comprehensive and well written review of fluconazole's role in the management of invasive and superficial fungal infections.
8. Grant SM, Clissold SP: Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989, 37:310-344.
9. Haria M, Bryson HM, Goa KL. Itraconazole: a reappraisal of its pharmacological properties and therapeutic use in the management of superficial infections. Drugs 1996, 51:585-620, A thorough review of itraconazole underlining its growing importance in the treatment of superficial, as opposed to invasive, fungal infections.
10. Rex JH, Bennett JE, Sugar AM, Pappas PG, Van Der Horst CM, Edwards JE, Washburn RG, Scheld WM, Karchmer AW, Dine AP et al.: A randomised trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994, 331:1325-1330.
11. Anaissie EJ, Vartivarian SE, Abi-Said D, Uzun O, Pinczowski H, Kontoyiannis DP, Khoury P, Papadakis K, Gardner A, Raad II et al.: Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 1996, 101:170-176.
12. Menichetti F, Fiorio M, Tosti A, Gatti G, Pasticci MB, Miletich MM, Bassetti D, Pauluzzi S: High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996, 22:838-840.
13. Cartledge JD, Midgley J, Gazzard BG: Itraconazole cyclodextrin solution; the role in in vitro susceptibility testing in predicting successful treatment of HIV-related fluconazole-resistant and fluconazole-susceptible oral candidiasis. AIDS 1997, 11:163-168.
14. Georgopapadakou NH, Walsh TJ: Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother 1996, 40:279-291. A useful summary of current and emerging antifungal targets and inhibitors and of immunological approaches to treating fungal infections.
15. Rex JH, Rinaldi MG, Pfaller MA: Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995, 39:1-8.
16. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, Lancaster M, Odds FC, Rinaldi MG, Walsh TJ, Barry AL for the Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards: Development of interpretative breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole and Candida infections. Clin Infect Dis 1997, 24:235-247. An excellent analysis of the relationship between in vitro susceptibility testing and clinical outcome for fluconazole and itraconazole against C. albicans. It draws on data that have accrued during the past decade and represents the benchmark for further in vitro-in vivo correlation studies in the antifungal area.
17. Takashima K, Oki T: Azole antifungal agents. Exp Opin Ther Patents 1996, 6:645-654. A useful, concise review of current and emerging triazole derivatives.
18. Dickinson RP, Bell AS, Hitchcock CA, Narayanaswami S, Ray SJ, Richardson K, Troke PF: Novel antifungal 2-aryl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol derivatives with high activity against Aspergillus fumigatus. Bioorg Med Chem Lett 1996, 6:2031-2036. This paper describes the key structure-activity relationships of exploratory triazoles, leading to the discovery of voriconazole and its potent antifungal activity in vitro and in vivo.
19. Hitchcock CA, Pye GW, Oliver GP, Troke PF: UK-109,496, a novel wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity and selectivity in vitro [abstract F72]. In Proceedings and Abstracts of the 35th Intersciences Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society for Microbiology: 1995:125.
20. Barchesi F, Restrepo M, McGough DA, Rinaldi MG: In vitro activity of a new antifungal triazole: UK-109,496 [abstract F71]. In Proceedings and Abstracts of the 35th Intersciences Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology: 1995:125.
21. Barry AL, Brown SD: In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrob Agents Chemother 1996, 40:1948-1949. This paper emphasises the potent activity of voriconazole relative to that of fluconazole against a wide range of Candida spp.
22. Murphy M, Bernard EM, Ishimaru T, Armstrong D: Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 1997, 41:696-698.
23. Ruhnke M, Schmidt-Westhausen A, Trautmann M: In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1997, 41:575-577. This paper emphasises that the potency advantage of voriconazole over fluconazole against Candida in vitro, translates to a clinical response to voriconazole in HIV patients with OPC refractory to fluconazole.
24. McGinnis MR, Pasarell L, Cooper CR: In vitro susceptibility of clinical mould isolates to UK-109,496, amphotericin B, fluconazole and itraconazole [abstract E76]. In Proceedings and Abstracts of the 35th Intersciences Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:99.
25. Espinel-Ingroff A, Flynn T: Antifungal activity of the new triazole voriconazole against established, new and emerging yeast pathogens [abstract F83]. In Proceedings and Abstracts of the 36th Intersciences Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society for Microbiology; 1996:114.
26. Espinel-Ingroff A: Evaluation of the in vitro activity of the new triazole voriconazole against opportunistic filamentous fungi [abstract F84]. In Proceedings and Abstracts of the 36th Intersciences Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1994:114.
27. Sutton DA, Fothergill AW, Barchiesi FJ, Rinaldi MG: In vitro activity of voriconazole against dimorphic fungi [abstract F85]. In Proceedings and Abstracts of the 36th Intersciences Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:114.
28. Radford SA, Johnson EM, Warnock DW: In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less common mould pathogens. Antimicrob Agents Chemother 1997, 41:841-843. This paper further highlights the broad-spectrum antifungal potency of voriconazole.
29. Jezequel SG, Clark M, Cole S, Evans KE, Wastall P: UK- 109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: pre-clinical pharmacokinetics [abstract F76]. In Proceedings and Abstracts of the 35th Intersciences Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:126.
30. Hitchcock CA, Andrews RJ, Lewis BGH, Troke PF: UK- 109,496, a novel, wide-spectrum triazole for the treatment of fungal infections: antifungal activity in experimental infections with Aspergillus [abstract F74]. In Proceedings and Abstracts of the 35th Intersciences Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:126.
31. Martin MV, Yates J, Hitchcock CA: Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother 1997, 41:13-16. This paper is a good illustration of how voriconazole's fungicidal mechanism of action against Aspergillus in vitro translates to cures in a guinea pig model of Aspergillus endocarditis.
32. Troke PF, Brammer KW, Hitchcock CA, Yonren S, Sarantis N: UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: activity in systemic candidiasis models and early clinical efficacy in oropharyngeal candidiasis [abstract F73]. In Proceedings and Abstracts of the 35th Intersciences Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:125.
33. Hitchcock CA, Andrews RJ, Lewis BGH, Troke PF: UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity in experimental infections with Cryptococcus [abstract F75]. In Proceedings and Abstracts of the 35th Intersciences Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:126.
34. George D, Miniter P, Andriole VT: Efficacy of UK-109,496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 1996, 40:86-91. This paper shows that although voriconazole is effective against invasive aspergillosis in rabbits, it is not as active as would be predicted from its potency in vitro. This reflects the rapid metabolism of voriconazole in this species, in contrast to guinea pigs and man.
35. Patterson BE, Coates PE: UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man [abstract F78]. In Proceedings and Abstracts of the 35th Intersciences Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:126.
36. Denning D, del Favero A, Gluckman E, Norfolk D, Ruhnke M, Yonren S, Troke PF, Sarantis N: UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in acute invasive aspergillosis [abstract F80]. In Proceedings and Abstracts of the 35th Intersciences Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:126.
37. Dupont B, Denning D, Lode H, Yonren S, Troke PF, Sarantis N: UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in chronic invasive aspergillosis [abstract F81]. In Proceedings and Abstracts of the 35th Intersciences Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:127.
38. Fromtling RA, Castaner J: SCH-56592. Drugs Future 1996, 21:160-166. A useful review of the pre-clinical profile of SCH 56592, drawing on data that have been published in abstracts or full papers during the past two years.
39. Parmegiani R, Cacciapuoti A, Loebenberg D, Antonacci B, Norris C, Yarosh-Tomaine T, Michalski M, Hare RS, Miller GH: In vitro activity of sch 56592, an orally active broad-spectrum antifungal agent [abstract F62]. In Proceedings and Abstracts of the 35th Intersciences Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:123.
40. Law D, Denning DW: In vitro activity of Schering 56592 compared with fluconazole and itraconazole against Candida spp. [abstract F88]. In Proceedings and Abstracts of the 36th Intersciences Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:115.
41. Dupont B, Improvisi L, Dromer F: In vitro and in vivo activity of a new antifungal agent SCH 56592 [abstract F93]. In Proceedings and Abstracts of the 36th Intersciences Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:116.
42. Perfect JR, Cox GM, Dodge RK, Schell WA: In vitro and in vivo efficacies of the azole SCH-56592 against Cryptococcus neoformans. Antimicrob Agents Chemother 1996, 40:1910-1913. This paper shows that the potent activity of SCH-56592 against Cryptococcus in vitro translates to good efficacy in a rabbit model of cryptococcal meningitis.
43. Galgiani JN, Lewis ML: In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob Agents Chemother 1997, 41:180-183. This paper shows that SCH-56592 has potent, itraconazole-like activity against a wide range of yeasts. It also highlights that the results of susceptibility tests in standard media may be influenced by the method used to solubilise SCH-56592 and itraconazole.
44. Pfaller MA, Messer S, Jones RN: Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob Agents Chemother 1997, 41:233-235. This paper demonstrates that SCH-56592 is at least equivalent to itraconazole and significantly more potent than fluconazole against a wide range of clinically important yeasts.
45. Fothergill AW, Sutton DA, Rinaldi MG: An in vitro head-to-head comparison of Schering 56592, amphotericin B, fluconazole and itraconazole against a spectrum of filamentous fungi [abstract F89]. In Proceedings and Abstracts of the 36th Intersciences Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:115.
46. Oakley KL, Morrissey G, Denning DW: Efficacy of SCH-56592 in 2 immunocompromised murine models of invasive aspergillosis [abstract F97]. In Proceedings and Abstracts of the 36th Intersciences Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:116.
47. Patterson TF, Kirkpatrick WR, Mcattee RK, Loebenberg D: Efficacy of SCH 56592 in a rabbit model of invasive aspergillosis [abstract F98]. In Proceedings and Abstracts of the 36th Intersciences Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:116.
48. Graybill J, Najvar L, Bocanegra R, Fothergill A, Luther M: Treatment of murine pulmonary aspergillosis with SCH 56592 [abstract F99]. In Proceedings and Abstracts of the 36th Intersciences Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:117.
49. Cacciapuoti A, Parmegiani A, Loebenberg D, Antonacci B, Moss EL, Menzel F, Norris C, Hare RS, Miller GH: Efficacy of SCH 56592 in pulmonary aspergillosis and candidiasis in mice [abstract F67]. In Proceedings and Abstracts of the 35th Intersciences Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:123.
50. Cacciapuoti A, Loebenberg D, Frank D, Moss EL, Menzel F, Michalski M, Norris C, Yaremko B, Hare RS, Miller GH: Effect of delayed or extended treatment with SCH 56592 or concomitant treatment with amphotericin B in murine models of pulmonary aspergillosis and systemic candidiasis [abstract F96]. In Proceedings and Abstracts of the 36th Intersciences Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1996:116.
51. Nomeir A, Kumari P, Hilbert MJ, Loebenberg D, Cacciapuoti A, Menzel I, Moss E, Hare R, Miller GH, Cayen N, Lin CC: Comparative pharmacokinetics of a new triazole antifungal agent Sch 56592 in mice, rats, rabbits, dogs and cynomolgus monkeys [abstract F68]. In Proceedings and Abstracts of the 35th Intersciences Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1995:124.
52. De Wit S, Dupont B, Cartledge JD, Hawkins DA, Gazzard BG, Clumeck N, Denning DW: A dose-comparison study of a new triazole antifungal (D0870) in HIV-positive patients with oral candidiasis. AIDS 1997, 11:759-763.